EXK Stock Overview
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EXK from our risk checks.
Exact Sciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.43 |
| 52 Week High | US$94.79 |
| 52 Week Low | US$51.27 |
| Beta | 1.23 |
| 1 Month Change | -1.81% |
| 3 Month Change | -1.10% |
| 1 Year Change | 1.92% |
| 3 Year Change | -48.29% |
| 5 Year Change | -33.12% |
| Change since IPO | 1,712.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| EXK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.0% | -0.2% | 0.5% |
| 1Y | 1.9% | -22.8% | 1.3% |
Return vs Industry: EXK exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: EXK matched the German Market which returned 2.3% over the past year.
Price Volatility
| EXK volatility | |
|---|---|
| EXK Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EXK has not had significant price volatility in the past 3 months.
Volatility Over Time: EXK's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Kevin Conroy | www.exactsciences.com |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Exact Sciences Corporation Fundamentals Summary
| EXK fundamental statistics | |
|---|---|
| Market cap | €10.70b |
| Earnings (TTM) | -€190.31m |
| Revenue (TTM) | €2.33b |
4.3x
P/S Ratio-52.3x
P/E RatioIs EXK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXK income statement (TTM) | |
|---|---|
| Revenue | US$2.50b |
| Cost of Revenue | US$654.25m |
| Gross Profit | US$1.85b |
| Other Expenses | US$2.05b |
| Earnings | -US$204.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 73.83% |
| Net Profit Margin | -8.17% |
| Debt/Equity Ratio | 75.2% |
How did EXK perform over the long term?
See historical performance and comparison